Decoy TherapeuticsFRA:FP11 23 EV-to-FCF is -0.34 as of Jul. 03, 2026. GuruFocus rates FRA:FP11 with a GF Score™ of 23/100. The stock has 3 warning signs investors should review. Among 332 Biotechnology companies, Decoy Therapeutics ranks worse than 301204.52% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Decoy Therapeutics's Enterprise Value is €1.93 Mil.
Decoy Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was €-5.62 Mil. Therefore, Decoy Therapeutics's EV-to-FCF for today is -0.34.
The historical rank and industry rank for Decoy Therapeutics's EV-to-FCF or its related term are showing as below:
FRA:FP11'
s EV-to-FCF Range Over the Past 10 Years
Min: -8.05 Med: 0.91 Max: 2.11
Current: -0.34
During the past 12 years, the highest EV-to-FCF of Decoy Therapeutics was 2.11. The lowest was -8.05. And the median was 0.91.
FRA:FP11's EV-to-FCF is ranked worse than 100% of 332
companies
in the Biotechnology industry
Industry Median: 16.26
vs FRA:FP11: -0.34
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Decoy Therapeutics's PE Ratio (TTM) for today is calculated as:
Decoy Therapeutics's share price for today is €5.232.
Decoy Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-106.760.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Decoy Therapeutics EV-to-FCF Related Terms
Decoy Therapeutics EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Decoy Therapeutics's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:FP11 vs ACUT, BIXT, CLDI: EV-to-FCF Comparison
For the Biotechnology subindustry, Decoy Therapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Decoy Therapeutics EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Decoy Therapeutics's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Decoy Therapeutics's EV-to-FCF falls into.
Decoy Therapeutics's current Enterprise Value is €1.93 Mil.
Decoy Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-5.62 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Decoy Therapeutics (FRA:FP11) has a EV-to-FCF of -0.34 as of Jul. 03, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Decoy Therapeutics and its competitors. According to the industry distribution chart, Decoy Therapeutics ranks #999999 out of 332 companies in the Biotechnology industry.
Is Decoy Therapeutics' EV-to-FCF too high?
Decoy Therapeutics' current EV-to-FCF is -0.34. Based on the distribution chart, Decoy Therapeutics ranks #999999 out of 332 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Decoy Therapeutics has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Decoy Therapeutics' EV-to-FCF compare to ACUT and BIXT?
According to the Biotechnology industry distribution chart, Decoy Therapeutics ranks #999999 out of 332 companies for EV-to-FCF. This places Decoy Therapeutics in the lower half of its industry. The industry median EV-to-FCF is 16.26. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 16.26, based on 332 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Decoy Therapeutics and its competitors. For the Biotechnology industry, the median EV-to-FCF is 16.26 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Decoy Therapeutics's current EV-to-FCF is -0.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Decoy Therapeutics stock overvalued right now?
Decoy Therapeutics (FRA:FP11) has a current EV-to-FCF of -0.34. The current EV-to-FCF is -0.34. Decoy Therapeutics' overall GF Score™ is 23/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Decoy Therapeutics (FRA:FP11), the current EV-to-FCF is -0.34 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Decoy Therapeutics Inc is a pre-clinical stage biotechnology company focused on advancing its pipeline of peptide conjugate therapeutics engineered through its proprietary IMP3ACT platform. The IMP3ACT platform represents a paradigm shift in peptide conjugate drug discovery and manufacturing, leveraging machine learning (ML) and artificial intelligence (AI" tools alongside high-speed synthesis techniques to rapidly engineer, optimize and manufacture peptide conjugates that target serious unmet medical needs. The company manages its business in one operating segment, focused on the discovery and development therapeutics for patients with high, unmet medical needs. Its pipeline programs include: Pan-Coronavirus; and Tripledemic.
23GF Score
Get the complete analysis for FRA:FP11
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:FP11 has been successfully added to your 
